Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Investigation of survival and migration potential of differentiated cardiomyocytes transplanted with decellularized heart scaffold.

Akbay E., Onur MA.

Animal Study on Cardiovascular Disease, published in J Biomed Mater Res A (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Biomed Mater Res A (2018)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
30390408
DOI
10.1002/jbm.a.36572

Abstract (original English)

Mesenchymal stem cell-derived cardiomyocytes are employed as a source for myocardial cell transplantation as well as for tissue engineering in decellularized tissue scaffolds. The present study aimed at investigating the survival and migration potential of differentiated cardiomyocytes integrated to decellularized scaffolds after implantation into retroperitoneum of rats, and to assess the feasibility of their ectopic use for future cardiovascular tissue engineering. For this purpose, adipose tissue-derived mesenchymal stem cells (AdMSCs) were first isolated. Cells were labeled by bromodeoxyuridine (BrdU). Decellularized cardiac tissue scaffolds were acquired by application of ionic and non-ionic detergents and the labeled differentiated cells were seeded onto these tested decellularized scaffolds. After 1, 2, and 4 weeks of implantation, either cell free scaffold (CFS) or cell scaffold (CS) composites were examined by various techniques for ectopic migration potential of the implanted cells and interaction between the seeded cells on scaffolds. Throughout the first and second weeks of implantation, positively stained cells were observed in renal tissue samples. Observations, for cardiomyocytes-specific gene expression during weeks 1, 2, and 4, showed potential increased over each time period. A reverse transcription polymerase chain reaction (RT-PCR) results revealed an increa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCell DifferentiationCell MovementCells, ImmobilizedMaleMyocardiumMyocytes, CardiacRatsRats, WistarTissue Scaffolds

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research